glp-1 amgen Ro Announces Research Collaboration to Better Understand and Improve the Real-World Patient Experience with GLP-1s Amgen's AMG-133 shows potential in
Description
2
There are a large number of studies that have reported the application of exendin-4, liraglutide and exenatide in the treatment of cognitive dysfunction and pathological features in AD models
In contrast, another study applying similar methodology in the same database for events between January 2018 and September 2022 reported a significant association of ileus cases with semaglutide (IC 025 3.04 [0.11 lower one-sided 95% CI]), but not for any other GLP-1RAs (94)
Novo Nordisk has similarly seen its stock rise 86% since Wegovy launched in 2021
